XML 135 R117.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Product Information [Line Items] |  |  |  |
Revenues |  | $ 16,544 | $ 15,846 | $ 14,925
United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 8,034 | 7,731 | 7,003
Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 5,103 | 4,837 | 4,525
International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 2,463 | 2,351 | 2,352
Generic products (including OTC and biosimilars) [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 3,599 | 3,138 | 3,155
Generic products (including OTC and biosimilars) [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 3,926 | 3,664 | 3,466
Generic products (including OTC and biosimilars) [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 1,937 | 1,932 | 1,980
AJOVY [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 207 | 211 | 210
AJOVY [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 216 | 160 | 124
AJOVY [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 84 | 63 | 42
AUSTEDO [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 1,642 | 1,225 | 963
AUSTEDO [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 46 | 15 | 8
BENDEKA and TREANDA [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 168 | 237 | 309
COPAXONE [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 242 | 297 | 359
COPAXONE [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 213 | 231 | 268
COPAXONE [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 48 | 63 | 64
UZEDY [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 117 | 23 | 0
Anda [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 1,536 | 1,577 | 1,471
Respiratory Product [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues |  | 244 | 265 | 273
Other [Member] | United States [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues | [1] | 523 | 1,025 | 536
Other [Member] | Europe [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues | [2] | 504 | 516 | 393
Other [Member] | International Markets [Member] |  |  |  |
Product Information [Line Items] |  |  |  |
Revenues | [3] | $ 349 | $ 278 | $ 257
[1] | Other revenues in 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s duvakitug (anti-TL1A) asset (see note 2).
[2] | Other revenues in 2024 and 2023 include the sale of certain product rights.
[3] | Other revenues in 2024 include the sale of certain product rights.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_UnitedStatesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_GenericsMediciansIncludingOtcAndBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AjovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AustedoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_COPAXONEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_UzedyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_RespiratoryProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |